|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Medicine (Ms. Carter and Dr. Banks), Section of Pulmonary and Critical Care Medicine, West Virginia University School of Medicine, Morgantown; and National Institute for Occupational Safety and Health (Drs. Ortega and Weissman), Morgantown, WV.
Correspondence to: Hector G. Ortega, MD, ScD, National Heart, Lung, and Blood Institute, Division of Lung Diseases, Two Rockledge Centre, 6701 Rockledge Dr, Ste 10018, Bethesda, MD 20892-7952
| Abstract |
|---|
|
|
|---|
Design, setting, and participants: A survey evaluating the current practice of SIC was mailed to 259 residency training programs in adult pulmonary diseases, allergy and immunology, and occupational medicine accredited in the United States and Canada during the year 2000.
Results: Forty-six percent (123 of 259 programs) participated. Ninety-two programs reported that patients with OA were seen during the previous year, 15 programs reported that SIC had been performed, and 10 programs reported that patients had been referred to other sites for SIC. A total of 259 patients underwent SIC. No unexpected adverse reactions were reported. Forty-one programs reported that they had been willing to undertake SIC but were unable to do so. The most common barriers cited were lack of availability of SIC within the evaluating institution, inability to locate a site for referral, concerns about reimbursement, and lack of an appropriate diagnostic reagent for use in SIC. Seventy-four programs indicated that SIC was useful, and 34 programs included training in the use of SIC was part of the residency curriculum.
Conclusion: Although SIC is considered the "gold standard" for objective documentation of OA, the test is performed in only a few institutions in the United States and Canada. Many institutions indicate that SIC is not available, even when desired for patient management. Only a minority of participating residency training programs include SIC as a formal part of the training curriculum.
Key Words: occupational asthma specific inhalation challenge residency training program
Work-related asthma has become the most prevalent occupational lung disease in industrialized countries.1 2 It has been classified into work-aggravated asthma, characterized by exacerbation of preexisting asthma at work; irritant-induced asthma, also known as reactive airways dysfunction syndrome; and sensitizer-induced occupational asthma (OA).3 OA is generally associated with a latency period of months to years between first exposure to an agent and development of immunologic sensitization and asthma.
The certainty of the diagnosis of OA depends on how well the physician proves that the worker has asthma, that asthma occurs in relation to workplace exposures, and that a specific sensitizing agent in the workplace has resulted in the development of this illness. Asthma is usually diagnosed by a combination of history, clinical findings during an exacerbation, and demonstration of bronchial hyperreactivity (BHR). BHR can be demonstrated by spirometric response to a bronchodilator, or spirometric response to a constrictor such as methacholine, histamine, or cold airfeatures typically, but not always, apparent in patients with OA.4 5
There is a substantial body of work that recognizes that physicians are frequently incorrect in demonstrating the relationship between asthma and the workplace. The clinical diagnosis of OA is difficult. Linkages between asthma and workplace exposures can be objectively assessed in several ways. Immunologic tests can document systemic sensitization to workplace allergens; however, they may also reflect an immune response to an agent unrelated to asthma. Serial ambulatory measurement of peak flow rates over a period of several weeks at work and then away from work can be used to document excessive variability while at work.6 Such serial peak flow measurements can assist in diagnosis of OA, yet difficulties in the interpretability and validity of records are frequently encountered.7 8 9 10
Serial measurements of BHR performed at work and then after at least 2 weeks away from exposure can be used to establish a linkage between workplace exposures and asthma. A significant lessening in BHR after removal from the workplace is supportive of a diagnosis of OA. However, in western red cedar workers, this approach was less helpful than peak flow monitoring.11 Potential problems with use of BHR for diagnosis of OA include sensitivity, as OA can occur without BHR.12 Specificity is a particularly important problem, as BHR can be caused by a number of processes other than OA, such as asthma unrelated to the workplace, allergic rhinitis, viral upper respiratory tract infections, and COPD.13 14 15 The sensitivity and specificity of BHR is influenced by the cutoff used to define an abnormal test result and the definition of asthma that is used. Nevertheless, the absence of BHR within 24 h of the workers usual respiratory symptoms with workplace exposure makes the diagnosis of OA exceedingly unlikely, and correlates well with negative peak flow results. Thus, serial BHR measurements at and then away from work may be a useful adjunct to serial peak flow monitoring, but careful clinical correlation is required.
Finally, specific inhalation challenge (SIC) with occupational agents conducted either in a laboratory or in the workplace can establish linkages between workplace exposures and asthma. In fact, SIC has been described as the "gold standard" for diagnosis of OA.16 In research settings, SIC has been used to investigate performance characteristics of other measures used to diagnose OA. For example, in one series, 63 isocyanate-exposed workers with a physicians diagnosis of OA were referred for SIC.17 Eighty-eight percent reported work-related respiratory symptoms and 97% noted an improvement in chest complaints when away from the workplace, yet only 33 workers had airway responsiveness following SIC with the offending agent. To make the diagnosis even more difficult, 43% of those who did not respond to SIC had BHR, confirming the fact that the measurement of nonspecific airway hyperresponsiveness may help in the diagnosis of asthma, but does not diagnose OA. Importantly, the surprisingly low percentage of patients clinically suspected of having OA who have a positive SIC finding to the suspected offending agent in the above-mentioned study (48%) is similar to data reported by others.18 19
It is a common perception that SIC is only performed in a few specialized centers in the United States. In this article, we sought to document usage of SIC in the United States and Canada by conducting a survey of representatives of three different types of academic residency training programs likely to use SIC in patient management: pulmonary and critical care medicine, allergy and clinical immunology, and occupational medicine. Queries focused on current practice and methods used to diagnose OA, perceptions about SIC, usage of SIC, and barriers to using SIC.
| Materials and Methods |
|---|
|
|
|---|
| Results |
|---|
|
|
|---|
|
|
In the programs in which serial peak flow measurements were used to diagnose OA, the mean length of peak flow monitoring was 14 days. Monitoring periods ranged from 2 to 60 days. Among those programs in which BHR was used to assist in diagnosis of OA, methacholine was the most commonly used nonspecific inhalation challenge test agent (67 of 92 programs; 73%). Histamine was used by 5% (5 of 92 programs), cold air by 2% (2 of 92 programs), exercise by 2% (2 of 92 programs), and carbachol by 1% (1 of 92 programs).
Representatives from 74 training programs expressed the opinion that SIC was useful, and 25 training programs reported that patients were studied by SIC or by referring them for the procedure (Table 1) . Indications for SIC reported by programs included identification of agents triggering respiratory symptoms (22 programs), compensation or legal reasons (14 programs), or academic reasons such as research or a case report (13 programs). Fifteen programs reported a total of 259 SIC procedures during the previous 12 months. Table 2 lists the specific location and contact of 12 of these programs; 3 programs asked that their locations not be disclosed. Of the 15 programs in which SIC was conducted, 154 procedures were performed in 6 pulmonary programs, 75 procedures were performed in 6 allergy programs, and 30 procedures were performed in 3 occupational medicine programs. With regard to generation of exposures to workplace agents, 87% (13 of 15 programs) of those in which SIC was performed used controlled laboratory exposures, 67% (10 of 15 programs) simulated workplace activity in the laboratory, and 7% (1 of 15 programs) used workplace challenge. Workplace agents reported to have been used in exposures are detailed in Table 3 . No serious adverse reactions to SIC were reported over the last 12 months by any of the respondents.
|
|
| Discussion |
|---|
|
|
|---|
Another potential problem in diagnosis of OA suggested by this survey is performance of ambulatory serial peak flow monitoring. A 1995 consensus statement6 suggested that to reliably establish a linkage between peak flow variability and work exposures, monitoring should be conducted for a minimum of 2 weeks at work and 2 weeks away from work. In contrast, the mean duration of peak flow monitoring reported by programs in response to this survey was 14 days, with one program reporting having used as little as 2 days. Monitoring of such short durations might result in substantial misclassification of patients as having OA. As a general rule, the duration of monitoring is dependent on severity of the disease, medications requirement, duration, compliance, and exposure situation. Serial peak flow measurements for such a short term may be insufficient to improve work-related peak flow variability, or the improvement, if any, following removal from work.
With regard to SIC, it is apparent that relatively few centers in the United States and Canada use this approach to linkage of workplace exposures and asthma. Furthermore, it is clear that SIC is used far more frequently in Canada than in the United States. Although SIC has been described by some authorities to be the "gold standard" test for objective confirmation of associations between workplace exposures and asthma, it is by no means perfect. A negative test result may not exclude the diagnosis of OA if the relevant exposure causing asthma at work is not reproduced. Either exposure to the wrong agent or wrong levels of an agent can lead to such false-negative reactions.21 False-negative reactions can also occur if workers have been removed from workplace exposures for a sufficient period of time to decrease reactivity to SIC.22 False-positive reactions can also occur to agents provided at "irritant" level.23 The imperfect performance characteristics of SIC, coupled with technical demands for generation of controlled exposures, test expense, and time required to perform tests, all likely contributed to the relatively small number of training programs in which the procedure was done. The markedly more frequent rate of use of SIC to diagnose OA in Canada than in the Unites States is likely related to differences in the legal and workers compensation systems of the two countries. However, our data suggest that demand does exist for increased access to SIC for diagnosis of OA.
There are several concerns regarding this work. One of the limitations of this survey is the low participation rate (47.5%). It is possible that the listing of the training programs conducting SIC is incomplete (Table 2) . Some programs in which SIC was conducted may not have responded to the survey. Despite of our efforts to increase the response rate, 53% of the pulmonary programs, 58% of the allergy programs, and 41% of the occupational medicine programs did not respond. Additionally, questions were limited to the "last 12 months" at the time of the survey; therefore, it is likely that SIC is no longer conducted in some programs.
In conclusion, our data suggest that suboptimal approaches are often used to establish the diagnosis of OA. Furthermore, even though some authorities have described SIC as the "gold standard" test for objective confirmation of associations between workplace exposures and asthma, the procedure is performed in only a small number of training programs. SIC is much more likely to be used to diagnose OA in Canada than in the United States, suggesting that issues related to the differing medical, legal, and compensation systems of the two countries impact on test usage. Finally, our data suggest that demand does exist for increased access to SIC for diagnosis of OA.
| Footnotes |
|---|
Received for publication August 10, 2001. Accepted for publication October 19, 2001.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. M. Tarlo Cough: Occupational and Environmental Considerations: ACCP Evidence-Based Clinical Practice Guidelines Chest, January 1, 2006; 129(1_suppl): 186S - 196S. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Mapp, P. Boschetto, P. Maestrelli, and L. M. Fabbri Occupational Asthma Am. J. Respir. Crit. Care Med., August 1, 2005; 172(3): 280 - 305. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Fink, H. G. Ortega, H. Y. Reynolds, Y. F. Cormier, L. L. Fan, T. J. Franks, K. Kreiss, S. Kunkel, D. Lynch, S. Quirce, et al. Needs and Opportunities for Research in Hypersensitivity Pneumonitis Am. J. Respir. Crit. Care Med., April 1, 2005; 171(7): 792 - 798. [Abstract] [Full Text] [PDF] |
||||
![]() |
J-L. Malo, A. Cartier, C. Lemiere, A. Desjardins, M. Labrecque, J. L'Archeveque, G. Perrault, J. Lesage, and Y. Cloutier Exaggerated bronchoconstriction due to inhalation challenges with occupational agents Eur. Respir. J., February 1, 2004; 23(2): 300 - 303. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Vandenplas, K. Toren, and P.D. Blanc Health and socioeconomic impact of work-related asthma Eur. Respir. J., October 1, 2003; 22(4): 689 - 697. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Koskela, A. Taivainen, H. Tukiainen, and H.-K. Chan Inhalation Challenge With Bovine Dander Allergens: Who Needs It? Chest, July 1, 2003; 124(1): 383 - 391. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Alberts Getting the Most From the "Gold Standard" Chest, April 1, 2003; 123(4): 987 - 989. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |